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Simple Summary: This experiment was designed to evaluate the differences in antimicrobial and
multidrug resistance dynamics in broilers reared under two different farm conditions (commercial
vs. improved) during the growing period, using Escherichia coli as sentinel bacterium. Although
no antibiotics were applied during rearing for two different management conditions tested, high
rates of antimicrobial and multidrug-resistant bacteria were observed throughout rearing, with the
percentages of resistant bacteria observed being of particular concern in day-old chicks on arrival
day and in chickens at the end of the growing period, just before delivery to the slaughterhouse.
Abstract: New measures applied to reduce antimicrobial resistances (AMR) at field level in broiler
production are focused on improving animals’ welfare and resilience. However, it is necessary to
have better knowledge of AMR epidemiology. Thus, the aim of this study was to evaluate AMR and
multidrug resistance (MDR) dynamics during the rearing of broilers under commercial (33 kg/m2
density and max. 20 ppm ammonia) and improved (17 kg/m2 density and max. 10 ppm ammonia)
farm conditions. Day-old chicks were housed in two poultry houses (commercial vs. improved),
and no antimicrobial agents were administered at any point. Animals were sampled at arrival day,
mid-period and at slaughter day. High AMR rates were observed throughout rearing. No statistical
differences were observed between groups. Moreover, both groups presented high MDR at slaughter
day. These results could be explained by vertical or horizontal resistance acquisition. In conclusion,
AMR and MDR are present throughout rearing. Moreover, although a lower level of MDR was
observed at mid-period in animals reared under less intensive conditions, no differences were found
at the end. In order to reduce the presence of AMR bacteria in poultry, further studies are needed to
better understand AMR acquisition and prevalence in differing broiler growing conditions.
Keywords: antimicrobial resistance; multidrug resistance; broiler; farm management; Escherichia coli
1. Introduction
Antimicrobial resistance (AMR) is one of the most significant threats to public health
worldwide. Indeed, the World Health Organisation published that by 2050, if effective
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interventions against the increase in AMR are not carried out, there could be more than
10 million deaths annually as a result of such resistance [1]. Increased awareness of the
health threats related to AMR has resulted in greater social demand for antibiotic-free food
production, especially antibiotic-free meat, in recent years [2–7].
The European Medicines Agency reported that Spain has been the European country
with the highest consumption of antimicrobial agents (AMAs) since data became avail-
able [8]. In this sense, it is claimed that the uncontrolled administration of AMAs in the
past, as treatment for infectious diseases or as a growth promoter, has resulted in an in-
creased multidrug resistance (MDR) presence in the food chain [9–11]. In fact, the notable
prevalence of colistin resistance is particularly worrying, due to its widespread use in
veterinary medicine over many years, as it is a last-resort AMA reserved to treat MDR
bacterial infections in human medicine [12].
However, due to the strict control of AMA administration since the National AMR
Plan was established in 2014, their consumption in animal production has halved [13].
Specifically, between 2015 and 2019, in poultry a reduction of 71% in total AMA admin-
istration was reported, along with a 95% falloff in colistin administration, recording the
largest European drop in consumption of critical AMAs [14].
These data are the result of the efforts carried out by the poultry sector to reduce
AMA administration at field level. Firstly, by avoiding the entry and spread of pathogen
microorganisms, improving biosecurity, farm management and vaccination protocols [15];
and secondly, by investing in more accurate and animal-friendly management systems,
achieving animals with a strengthened immune system and more resilient to contact with
infectious agents [16–19]. To this end, the use of alternative production systems has been
promoted, focused on slow-growing breeds selected for their ability to deal with the
natural environment [20], and the implementation of less intensive production systems,
more sustainable and animal-welfare-friendly, but also maintaining the profitability of
broiler farms [21,22].
However, to be able to assess the effectiveness of these measures, it is necessary to
have better knowledge of the epidemiology of AMR throughout the growing period under
different farm conditions [23,24]. For this purpose, commensal Escherichia coli has typically
been selected as AMR sentinel, as it provides valuable data and constitutes a reservoir of
resistance genes, which can spread to zoonotic and other bacteria [20,25].
Nevertheless, further studies are still needed to achieve more resilient animals to
ensure that AMA administration continues to decrease at field level. In this context, the
aim of this study was to evaluate the AMR and MDR dynamics in broiler chickens during
the rearing period under two different management conditions (commercial vs. improved),
using Escherichia coli as sentinel bacterium.
2. Materials and Methods
In this experiment, animals were handled according to the principles of animal care
published by Spanish Royal Decree 53/2013 [26]. Moreover, all protocols were approved by
the Ethical Review Panel of the Directorate-General for Agriculture, Fisheries and Livestock
from the Valencian Community, by the code 2018/VSC/PEA/0067.
2.1. Experimental Design
The study was carried out in an experimental poultry farm at the Centre for Research
and Animal Technology (CITA-IVIA, in its Spanish acronym Valencian Institute for Agrarian
Research, Segorbe, Spain). The cleaning and disinfection protocol applied in the poultry
farm was according to the Kersia Group protocol [27]. The product used to clean the
poultry houses was Hyprelva Net Plus (Hypred S.L., Orcoyen, Spain), and the product
employed to disinfect them was Virobacter (Hypred S.L., Orcoyen, Spain). Finally, the
product used to disinfect the pipelines was Deptal SMP 5% (Hypred S.L., Orcoyen, Spain).
A total of 1062 day-old chicks (Ross®) (males and females) were housed in two
identical poultry houses (531 animals in each house). Within each of the houses, 204 animals
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were located in 12 pens and the rest of them (327) were on the floor out of the pens, all
with wood shavings as bedding material. Moreover, two different management conditions
were evaluated: commercial farm conditions (CFC, house 1) and improved farm conditions
(IFC, house 2). In house 1 (CFC) animals were kept at 33 kg/m2 density and non-optimal
parameters of ventilation were applied (allowing a maximum concentration of ammonia of
20 ppm), while in house 2 (IFC) chicks were kept at 17 kg/m2 density and ventilation was
provided within the optimal parameters (allowing a maximum concentration of ammonia
of 10 ppm). Ammonia concentration was continuously measured from the air, using a
Exafan climatic sensor DOL 53, installed near the outlet to obtain representative values
of the room concentrations. Moreover, both houses were equipped with programmable
electrical lights, automated electric heating and forced ventilation. The lighting program
was decreasing from 23L:1D on the arrival day to 16L:8D from day 15 to the end of the
growing period. Light intensity was guaranteed to be at least 20 lux in all parts of the
farm at the height of the animals, and the light was provided through white bulb lamps
uniformly distributed throughout the poultry house. The environmental temperature was
set at 32 ◦C on arrival day and gradually reduced to 19 ◦C by 41 days post hatching in line
with common practice in poultry production.
Day-old chicks were vaccinated in the hatchery against Gumboro disease, Marek disease
and infectious bronchitis (IBV). During the growing period, no vaccines were administered.
Animals received drinking water and were fed ad libitum; feed was weighed and
distributed manually. Two different age commercial diets were used to meet animals’
metabolic requirements (Table 1): from arrival day until 21 days post hatch, a pelleted
starter diet was offered to the birds (Camperbroiler iniciación, Alimentación Animal Nanta,
Valencia, Spain), and from 21 days old until slaughter day they were fed a pelleted grower
diet (A-32 broiler, Alimentación Animal Nanta, Valencia, Spain). Nutritional and product
analysis were assessed before the arrival of animals and only one batch of feed per age was
manufactured. Moreover, no coccidiostats or AMAs were added to either diet, and high
biosecurity levels were maintained in the experimental poultry house during the rearing.
Finally, the mortality rates and presence of diarrhea were registered daily, and animals’
weight and feed consumption were recorded at weekly intervals.
Table 1. Composition of starter and grower diets.
Analytical Constituents
Diet
Starter (d 1–21) (%) Grower (d 22–42) (%)
Crude Fat 3.5 3.1
Crude Protein 20.5 19.4
Crude Fibre 2.6 3.1




Phosphorus Available 0.69 0.51
Sodium 0.15 0.14
Ingredients








To evaluate the dynamic of AMR rates in the microbiota of broilers throughout the
growing period, commensal E. coli was selected as sentinel bacterium [20,25].
For this purpose, animals were randomly selected from each experimental group and
caeca samples were collected. Three different sampling moments were established: at
arrival (day-old chicks), at the mid-period (21 days old) and at the end of the production
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cycle (42 days of age). On arrival day, animals were selected and sampled just before being
delivered to the houses (30 samples). Then, cecal samples were collected per each treatment
(60 samples farm condition/house). Caeca were taken individually and placed in sterile
jars. Samples were processed within 24 h after collection.
2.3. E. coli Isolation
First, cecal content was removed and homogenized. Then, pools of six animals from
the same experimental group were prepared: 5 pools from day-old-chicks (30 samples),
10 pools from animals in CFC at mid-period (60 samples), 10 from animals in IFC at
mid-period (60 samples), 10 pools from animals in CFC at the end of the growing period
(60 samples) and 10 pools from animals in IFC at the end of the growing period (60 samples).
The pools’ content was cultured directly onto a Coliform Chromogenic agar (Scharlab,
S.L., Barcelona, Spain) in duplicate, and agar plates were incubated at 37 ± 1 ◦C for 24 h.
After incubation, suspected colonies were streaked onto a nutrient medium (Scharlab, S.L.,
Barcelona, Spain) and incubated at 37 ± 1 ◦C for 24 h. Then, API-20E test (Biomerieux, S.L.,
Barcelona, Spain) was performed to confirm E. coli.
2.4. Antimicrobial Susceptibility Testing
The protocol established to study the antimicrobial susceptibility of the isolates was ac-
cording to Montoro-Dasi et al. (2020) [20]. Briefly, the bacteria were inoculated onto
Mueller-Hinton agar (Scharlab, S.L., Barcelona, Spain) and the antibiotic discs were
added. Plates were incubated at 37 ± 1 ◦C for 24 h. The analysis was carried out
according to the European Committee on Antimicrobial Susceptibility Testing guide-
lines [28] and the source for zone diameters used for interpretation of the test was:
http://www.eucast.org/clinical_breakpoints/ (15 September 2020). The AMAs selected
were those set forth in Decision 2013/652 [29], including ciprofloxacin (CIP, 5 µg), nalidixic
acid (NAL, 30 µg), ampicillin (AMP, 10 µg), cefotaxime (CTX, 30 µg), ceftazidime (CAZ,
30 µg), chloramphenicol (CHL, 5 µg), trimethoprim-sulfamethoxazole (SXT, 1.25/23.75 µg),
colistin (CST, 10 µg), azithromycin (AZM, 15 µg), tigecycline (TGC, 15 µg), gentamycin
(GEN, 10 µg) and trimethoprim (TMP, 5 µg). MDR was defined as acquired resistance to at
least one agent in three or more antimicrobial classes [20,25].
2.5. Statistical Analysis
Statistical Analysis was performed according to Montoro-Dasi et al. (2020) [20]. A
Generalized Linear Model (GLM) test was used to compare the AMR and MDR rates
between farm conditions (CFC vs. IFC) and between sampling moments (arrival day,
mid-period and slaughter day). To do so, we fitted GLM where the occurrence of resistance
was the response variable and experimental group was the fixed effect. For this analysis,
the error was designated as having a binomial distribution and the probit link function was
used. Binomial data for each sample were assigned 1 if the E. coli isolates were resistant or
0 if not. Similarly, AMR rates of each antibiotic throughout the growing period (arrival day,
mid-period and slaughter day) were evaluated, using a GLM as previously. A p-value of
<0.05 was considered to indicate a statistically significant difference. Analyses were carried
out using a commercially available software application (SPSS 24.0 software package, SPSS
Inc., Chicago, IL, USA, 2002).
3. Results
During this experiment, all the productive parameters, including mortality rates,
animals’ weight, feed intake and feed conversion rate (Table 2), were according to the breed
standards [30] and no intestinal signs or disease were observed. Thus, no AMAs were
administered. In this study, a total of 45 pools of cecal content were analyzed in duplicate,
and all of them were culture-positive for E. coli (n = 90).
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Table 2. Mortality rate (MR), body weight (BW), feed intake (FI) and feed conversion rate (FCR) of
the animals for both experimental groups—commercial farm conditions (CFC) and improved farm




MR (%) BW (g) FI (Kg) FCR MR (%) BW (g) FI (Kg) FCR
7 1.47 157.73 0.13 1.19 0.98 160.42 0.13 1.12
14 0.50 413.17 0.37 1.35 1.49 428.59 0.36 1.38
21 0 788.25 0.71 2.02 0 789.15 0.67 1.89
28 0 1234.59 1.17 2.66 0 1233.51 1.09 2.46
35 0 1810.06 1.45 2.54 0 1788.30 1.27 2.27
42 0 2471.14 1.51 2.25 0 2461.13 1.36 2.09
3.1. Prevalence of Antimicrobial Resistance and Multidrug Resistance
From all E. coli isolates, 83.3% (n = 75/90) were resistant to at least one of the 12 AMAs
tested, and no statistically significant differences were found between replicates. In addition,
no statistically significant differences were found between the percentage of resistant E. coli
strains isolated from the two sampling groups (CFC vs. IFC) (p-value > 0.05) (Figure 1).
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Figure 1. Antimicrobial resistant E. coli isolates dynamic for commercial (CFC) and improved
farm conditions (IFC) throughout the growing period. No statistically significant differences
were observed.
Furthermore, 57.3% of the resistant isolates (n = 43/75) showed a MDR pattern, with
statistically significant differences between experimental groups (Figure 2). At the onset
of the growing period, 62.5% of the isolates (n = 5/8) were MDR. For CFC, similar rates
were maintained until the end of rearing, with a total of 68.8% (n = 11/16) and 57.9% (n
= 11/19) of MDR isolates at mid-period and on slaughter day, respectively. However, for
IFC group there were statistically significant differences between sampling moments (p <
0.05): mid-period samples (14.3%, n = 2/14) displayed a lower level of MDR isolates than
those obtained from animals at end of the growing period (77.8%, n = 14/18). Moreover,
when the percentages of MDR were analyzed between experimental groups, statistically
significant differences were found at mid-period (p < 0.05).
Animals 2021, 11, 1005 6 of 11
Animals 2021, 11, x 6 of 11 
 
 
Figure 2. Multidrug-resistant E. coli isolates dynamic for commercial (CFC) and improved farm 
conditions (IFC) throughout the growing period. a,b: Different superscripts means significant dif-
ferences within group with a p-value < 0.05. A,B: Different superscripts indicate significant differ-
ences between groups with a p-value < 0.05. 
E. coli AMR rates obtained against the different AMAs tested over time for both ex-
perimental groups are described in Table 3. 
Table 3. Antimicrobial resistance rates obtained for each antibiotic in different sampling moments 






CIPNALCTX CAZ AMP CHL SXT CSTAZM TGC GENTMP
CFC 
Arrival day 10 70 a 70 0 0 50 0 30 ab 0 0 b 0 30 bc 40 a 
Mid-period 20 60 a 75 0 0 30 0 55 a 0 0 b 0 10 c 55 a 
End 20 60 a 65 0 2 45 0 10 b 0 1 ab 0 75 a 60 a 
IFC 
Arrival day 10 70 a 70 0 0 50 0 30 ab 0 0 b 0 30 bc 40 a 
Mid-period 20 30 b 55 0 0 20 0 10 b 0 0 b 0 15 c 10 b 
End 20 50 a 65 0 4 35 0 35 a 0 5 a 0 65 ab 55 a 
a,b,c: Different superscripts in each antibiotic means significant differences with a p-value < 0.05. n: 
total of isolates from each experimental group in each sampling moment. CFC: Commercial farm 
conditions, IFC: Improved farm conditions, CIP: ciprofloxacin, NAL: nalidixic acid, AMP: ampicil-
lin, CTX: cefotaxime, CAZ: ceftazidime, CHL: chloramphenicol, SXT: trimethoprim-sulfamethoxa-
zole, CST: colistin, AZM: azithromycin, TGC: tigecycline, GEN: gentamycin, TMP: trimethoprim. 
3.2. Antimicrobial Resistance Patterns 
AMR patterns are described in Figure 3. At the arrival day, 20% (n = 2) of the isolates 
were susceptible to all the AMAs tested, 10% (n = 1) of the isolates were resistant to only 
1 AMA, 20% (n = 2) to 2, 20% (n = 2) to 4, 20% (n = 2) to 5, and 10% (n = 1) to 6. 
For CFC, 25% (n = 5) of the isolates were completely susceptible, 2.5% (n = 1) were 
resistant to one of the 12 AMAs tested, 10% (n = 4) to 2, 15% (n = 6) to 3, 32.5% (n = 13) to 
4, 10% (n = 4) to 5, 5% (n = 2) to 6, and only 2.5% (n = 1) were resistant to 8 of the AMAs 
tested. 
Finally, for IFC, 20% (n = 8) of the E. coli isolates were susceptible to all the AMAs 
analysed, 22.5% (n = 9) of the isolates were resistant to 1 AMA, 10% (n = 4) to 2, 15% (n = 
6) to 3, 17.5% (n = 7) to 4, 7.5% (n = 3) to 5, 5% (n = 2) to 6, and only 2.5% (n = 1) were 
resistant to 8 of the AMAs tested. 
Figure 2. Multidrug-resistant E. coli isolates dynamic for commercial (CFC) and improved farm
conditions (IFC) throughout the growing period. a,b: Different superscripts means significant
differences within group with a p-value < 0.05. A,B: Different superscripts indicate significant
differences between groups with a p-value < 0.05.
E. coli AMR rates obtained against the different AMAs tested over time for both
experimental groups are described in Table 3.
Table 3. Antimicrobial resistance rates obtained for each antibiotic in different sampling moments and experimental groups
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Figure 3. Number of E. coli strains isolated resistant to the different number of antimicrobials
tested and their antimicrobial resistance pattern, according to commercial (CFC) and improved (IFC)
farm conditions. n: total number of isolates from each experimental group. AMR: antimicrobial
resistances, AD: arrival day, CFC: Commercial farm conditions, IFC: Improved far conditions,
CIP: ciprofloxacin, NAL: nalidixic acid, AMP: ampicillin, CTX: cefotaxime, CAZ: ceftazidime, CHL:
chloramphenicol, SXT: trimethoprim-sulfa ethoxazole, CST: colistin, AZM: azithromycin, TGC:
tigecycline, GEN: gentamycin, TMP: trimethoprim.
4. Discussion
Despite the fact that no AMAs were administered during the experiment, it was
observed that 83.3% of E. coli isolates obtained were AMR, and 57.3% of them were MDR,
with slight variations between sampling moments. These data are in line with those
reported by the last European Food Safety Authority (EFSA) report [11], and could be
explained by a vertical or a horizontal resistance acquisition from breeders [31,32] or the
environment [20,33], respectively.
At the beginning of the study, on arrival day, the animals presented 80% of resistant
E. coli isolates, and 62.5% of them were MDR. These results show the importance of
AMR and MDR acquired from the breeding, hatching or transport environment [34,35]. It
has been reported that day-old chicks could be colonized by direct vertical transmission
through breeders’ microbiota [36] or by the resistant bacteria persistent in the hatchery or
on delivery transport surfaces [33,37,38], as they are an important threat requiring strict
management control in the initial stages to reduce the selective AMR/MDR pressure on
breeders, hatcheries and farm environments [9,39].
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Among the most relevant results observed in the dynamics of AMAs studied, the
highest resistances were observed against ciprofloxacin, nalidixic acid and ampicillin, in
line with results reported by the EFSA [11]. It is important to highlight the absence of
bacteria resistant to colistin and trimethoprim, as they are critically important AMAs,
reserved to treat serious infections caused by MDR bacteria in human medicine [1]. These
results reveal that the strategies implemented by governments and poultry industry to
control the use of critical AMAs, such as “stop-colistin”, are having an important effect at
field level [40]. In line with these findings, further efforts are needed to achieve a greater
decrease in the use of other AMAs.
Moreover, in this study at the end of the growing period, resistant bacteria to cef-
tazidime and azithromycin appeared, and the resistant bacteria to gentamycin and trimetho-
prim increased. This could be explained by horizontal transmission of resistance genes
from the environment, which is considered a critical point in livestock production. Several
authors demonstrated that horizontal transmission of resistances from the environment
could be more important than vertical transmission in broiler production [33]. In fact, pre-
vious studies demonstrated that residual feces or dust are important reservoirs for resistant
bacteria and AMR genes between different flocks in commercial farms due to the high
survival of resistant microorganisms after cleaning and disinfection procedures [41–44],
with the application of proper cleaning and disinfection protocols being mandatory to
avoid the survival of bacteria [45,46].
In this regard, it is demonstrated that an increase in animal welfare promotes the
presence of beneficial microbiota and the integrity of the intestinal epithelium. As a con-
sequence, the protective mechanisms are working perfectly and the interactions between
environmental and intestinal bacteria are reduced. In contrast, stress situations such as
the arrival to new facilities or the high-density levels presented at the end of the growing
period reduce the effectiveness of these protective mechanisms, increasing the colonization
of potential pathogens and resistant bacteria to the intestinal tract of broilers, increasing
interactions and transmission of resistant genes [47–50]. In this sense, animal welfare could
be considered as preventive medicine, promoting immunologically stronger animals that
are better able to cope with infectious diseases without administration of AMAs [15,48,51].
However, in this study it was observed that although animals subjected to less intensive
production conditions showed a lower level of MDR at mid-period, at the end of the grow-
ing stage the presence of AMR and MDR was particularly high, regardless of the poultry
being under less or more intensive conditions, at around 70% and 77.8%, respectively. This
fact could be explained by the high AMR rates on the arrival day, and the short time of rear-
ing (42 days), highlighting the importance of controlling the use of AMAs in the first stages
of the poultry production system [39]. In addition, it is important not to forget that at the
end of the growing period, when the highest levels of AMR have been observed, animals
are handled for transport to the slaughterhouse, which could involve an increase in stress,
intestinal dysbiosis and excretion of microorganisms in feces just before processing of the
carcasses, constituting an important threat to consumers [52–55]. Therefore, it is essential
to develop more accurate and cost-effective techniques to be applied at farm level to avoid
the presence of AMR and MDR microorganisms upon arrival at the slaughterhouse.
5. Conclusions
In conclusion, AMR and MDR are present throughout the growing period, although
no AMAs were administered. Moreover, although a lower level of MDR was observed at
mid-period in animals reared under less intensive farming conditions, no differences were
found between the two experimental groups at the end of the growing period. Further
studies are needed to evaluate how management could reduce the presence of AMR and
MDR bacteria in poultry production at all production stages.
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